Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on delivering oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years.
Company Details
- Employees
- 250
- Founded
- -
- Address
- 500 North Beacon Street,
- in****@****atx.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- kymeratx.com
- HQ
- Watertown, MA
Kymera Therapeutics Questions
Kymera Therapeutics's website is kymeratx.com
Kymera Therapeutics's LinkedIn profile is https://www.linkedin.com/company/kymeratherapeutics
Kymera Therapeutics has
250 employees.
View email and phone details for 250
employees at Kymera Therapeutics.
Kymera Therapeutics's industry is
Biotechnology Research
Kymera Therapeutics's top competitors are
Sarepta Therapeutics,
Entrada Therapeutics,
Verve Therapeutics,
Relay Therapeutics,
Alnylam Pharmaceuticals,
Tango Therapeutics,
Vertex Pharmaceuticals,
Tessera Therapeutics,
Beam Therapeutics,
Intellia Therapeutics, Inc..
Kymera Therapeutics's support email address is inquiries@kymeratx.com
Kymera Therapeutics's categories are Biotechnology Research
Kymera Therapeutics's founding year is 2016
